Posts

Vir’s hepatitis D drug combination succeeds in first pivotal study

on
Vir Biotechnology reported that its experimental combination of elebsiran and tobevibart met the primary endpoint in the Phase 3 ECLIPSE 1 trial, its first pivotal study in chronic hepatitis D. At Week 48, 44% of patients who began the combination immediately had both undetectable hepatitis D virus RNA and normalized ALT, a liver enzyme. No patients in the delayed-treatment group met that combined endpoint at Week 12 (p<0.0001). A key secondary measure showed 79% of patients on the combination had undetectable virus at Week 48. The trial enrolled 124 patients. The result is an important step toward a possible filing, but the drugs are still investigational. Vir is also studying the combination in two other pivotal trials and has said it plans to use all three studies in a potential U.S. application. Sources: Vir Biotechnology, Inc. - Vir Biotechnology Announces ... Vir says hepatitis D drug combination succeeds in first pivotal study Press Release of the Company, dated...

Network Bio and Duke team up to build AI disease models

on

Moderna raises growth outlook as vaccine sales and newer products gain momentum

on

Ziltivekimab lowered inflammation markers, but ZEUS found no cardiovascular-event benefit

on

Moderna’s COVID vaccine sales power a Q3 revenue beat

on

Chai Discovery adds Roche to its AI drug-discovery partnerships

on

FDA expands J&J’s Rybrevant Faspro beyond lung cancer

on

Novartis reports seven newly disclosed tumor cases among Zolgensma patients

on

GeneDx and Mirum launch no-cost genetic testing programs

on

Inovia Bio launches InovaMine for clinical data analysis and drug development

on

AstraZeneca reportedly offers about $10B for Rhythm

on

Evommune licenses Hinova’s VAV1 drug candidate in deal worth up to $1.1 billion

on

RASONQUE brings in nearly $198 million in its first five weeks

on